Examining cognitive changes in brain tumor patients receiving radiation therapy
Longitudinal Prospective Study of Neurocognitive Outcomes and Multimodal Quantitative Neuroimaging Outcomes in Primary Brain Tumor Patients Receiving Brain Radiotherapy
This study is trying to see how radiation therapy affects thinking and memory in people with brain tumors over time, so that doctors can improve treatment and help patients keep their cognitive skills.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | University of California, San Diego Academic / other |
| Drugs / interventions | radiation, chemotherapy |
| Locations | 1 site (San Diego, California) |
| Trial ID | NCT05576103 on ClinicalTrials.gov |
What this trial studies
This observational study aims to prospectively analyze primary brain tumor patients undergoing fractionated radiation therapy. It will utilize quantitative neuroimaging and neurocognitive testing to assess changes in brain function and structure over time. The goal is to correlate radiation exposure with cognitive outcomes, ultimately informing strategies to minimize cognitive decline associated with treatment. By identifying sensitive brain regions affected by radiation, the study seeks to enhance future radiation techniques for better patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a primary brain tumor who are scheduled to receive fractionated partial brain radiation therapy.
Not a fit: Patients who have previously undergone brain radiation therapy or cannot undergo MRI with contrast may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved radiation therapy techniques that spare cognitive function in brain tumor patients.
How similar studies have performed: While there have been studies examining cognitive effects of radiation, this specific approach using advanced neuroimaging techniques is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients 18 years or older 2. Karnofsky performance status (KPS) ≥70 3. Life expectancy of ≥1 year 4. Primary brain tumor patients who will receive fractionated partial brain RT 5. Able to complete neurocognitive assessments Exclusion Criteria: 1. Inability to undergo MRI with contrast 2. Prior brain RT
Where this trial is running
San Diego, California
- Moores Cancer Center — San Diego, California, United States (Recruiting)
Study contacts
- Study coordinator: Sheila Medina
- Email: s4medina@health.ucsd.edu
- Phone: 858-822-6575
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.